GO-203 25mg | Purity Not Available
Selleck Chemicals
GO-203 is a D-amino acid cell-penetrating peptide inhibitor of MUC1-C dimerization and thereby its oncogenic function.
More Information Supplier PageGO-203 is a D-amino acid cell-penetrating peptide inhibitor of MUC1-C dimerization and thereby its oncogenic function.
More Information Supplier PageSelective JAK3 inhibitor 1 is an irreversible JAK3 inhibitor with Ki values of 0.07 nM, 320 nM, 740 nM for JAK3, JAK1 and JAK2 respectively. It is also selective over the other kinases possessing a cysteine in the same region as JAK3, such as BMX, EGFR, ITK, and BTK.
More Information Supplier PagePemrametostat (GSK3326595, EPZ015938) is an orally active, potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) and potently inhibits tumor growth in vitro and in vivo in animal models.
More Information Supplier PageSkp2 inhibitor C1 (SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.
More Information Supplier PageSkp2 inhibitor C1 (SKPin C1) is a specific and selective small-molecule inhibitor of Skp2-mediated p27 degradation by reducing p27 binding through key compound-receptor contacts.
More Information Supplier PagebpV (HOpic) (Bisperoxovanadium (HOpic)) is a potent inhibitor of PTEN with an IC50 of 14 nM. The IC50s for PTP-β and PTP-1B are about 350- and 1800-fold higher than the IC50 for PTEN, respectively.
More Information Supplier PagebpV (HOpic) (Bisperoxovanadium (HOpic)) is a potent inhibitor of PTEN with an IC50 of 14 nM. The IC50s for PTP-β and PTP-1B are about 350- and 1800-fold higher than the IC50 for PTEN, respectively.
More Information Supplier PageBTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.
More Information Supplier PageBTSA1 is a pharmacologically optimized BAX activator that binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to BAX leading to BAX-mediated apoptosis. It effectively promotes apoptosis in leukemia cell lines and patient samples while sparing healthy cells.
More Information Supplier PageACY-738 inhibits HDAC6 with low nanomolar potency (IC50=1.7 nM) and a selectivity of 60- to 1500-fold over class I HDACs.
More Information Supplier Page